Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.


Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.

Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, Cwynarski K; British Society for Haematology.

Br J Haematol. 2019 Feb;184(3):348-363. doi: 10.1111/bjh.15661. Epub 2018 Nov 23. No abstract available.


Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP.

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. No abstract available.


Cardiac dysfunction in cancer survivors unmasked during exercise.

Kearney MC, Gallop-Evans E, Cockcroft JR, Stöhr EJ, Lee E, Backx K, Haykowsky M, Yousef Z, Shave R.

Eur J Clin Invest. 2017 Mar;47(3):213-220. doi: 10.1111/eci.12720. Epub 2017 Jan 30.


Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.

Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW.

Br J Haematol. 2016 Apr;173(2):274-82. doi: 10.1111/bjh.13954. Epub 2016 Feb 5.


Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma.

McKay P, Fielding P, Gallop-Evans E, Hall GW, Lambert J, Leach M, Marafioti T, McNamara C; British Committee for Standards in Haematology.

Br J Haematol. 2016 Jan;172(1):32-43. doi: 10.1111/bjh.13842. Epub 2015 Nov 5. No abstract available.


Recommendations for Radiotherapy Technique and Dose in Extra-nodal Lymphoma.

Hoskin PJ, Díez P, Gallop-Evans E, Syndikus I, Bates A, Bayne M; Participants of the National Cancer Research Institute Lymphoma Radiotherapy Group.

Clin Oncol (R Coll Radiol). 2016 Jan;28(1):62-8. doi: 10.1016/j.clon.2015.09.005. Epub 2015 Oct 9.


The role of alisertib in treatment of peripheral T-cell lymphomas.

Gallop-Evans E.

Future Oncol. 2015 Sep;11(18):2515-24. doi: 10.2217/fon.15.154. Epub 2015 Sep 7. Review.


4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I.

Lancet Oncol. 2014 Apr;15(4):457-63. doi: 10.1016/S1470-2045(14)70036-1. Epub 2014 Feb 24.


British HIV Association guidelines for HIV-associated malignancies 2014.

Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D, Collins S, Cwynarski K, Edwards S, Fields P, Fife K, Gallop-Evans E, Kassam S, Kulasegaram R, Lacey C, Marcus R, Montoto S, Nelson M, Newsom-Davis T, Orkin C, Shaw K, Tenant-Flowers M, Webb A, Westwell S, Williams M; British HIV Association.

HIV Med. 2014 Mar;15 Suppl 2:1-92. doi: 10.1111/hiv.12136. No abstract available.


A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.

Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 study investigators.

Br J Haematol. 2013 Nov;163(3):334-42. doi: 10.1111/bjh.12537. Epub 2013 Aug 23. Erratum in: Br J Haematol. 2014 May;165(3):422. Verhoef, Gregor [added].


Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.

Lütgendorf-Caucig C, Fotina I, Gallop-Evans E, Claude L, Lindh J, Pelz T, Knäusl B, Georg D, Pötter R, Dieckmann K; EuroNet-PHL RT Group.

Strahlenther Onkol. 2012 Nov;188(11):1025-30. doi: 10.1007/s00066-012-0182-4. Epub 2012 Oct 10.


Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.

Powell JR, Dojcinov S, King L, Wosniak S, Gerry S, Casbard A, Bailey H, Gallop-Evans E, Maughan T.

Leuk Lymphoma. 2013 May;54(5):959-66. doi: 10.3109/10428194.2012.733875. Epub 2012 Oct 16.


U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.

Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM.

Br J Dermatol. 2013 Jan;168(1):192-200. doi: 10.1111/bjd.12042. Epub 2012 Dec 3.


Primary central nervous system lymphoma.

Gallop-Evans E.

Clin Oncol (R Coll Radiol). 2012 Jun;24(5):329-38. doi: 10.1016/j.clon.2012.02.009. Epub 2012 Mar 27. Review.


Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A; 405 Study Investigators.

Blood. 2012 Apr 19;119(16):3698-704. doi: 10.1182/blood-2011-09-378323. Epub 2012 Mar 2.


Correlates of fertility issues in an internet survey of cancer survivors.

Tschudin S, Bunting L, Abraham J, Gallop-Evans E, Fiander A, Boivin J.

J Psychosom Obstet Gynaecol. 2010 Sep;31(3):150-7. doi: 10.3109/0167482X.2010.503910.


Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.

Parker K, Gallop-Evans E, Hanna L, Adams M.

Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):140-6. doi: 10.1016/j.ijrobp.2008.06.1920. Epub 2008 Oct 14.


Supplemental Content

Loading ...
Support Center